hers glp-1 Hims & swings to a loss in Q1 amid shift in strategy What to know about a

Monogenic parkinsons disease: genotype, phenotype, pathophysiology, and genetic testing

Hepatol Baltim Md 22:767773 Black M (1984) Acetaminophen hepatotoxicity

The median GPX-3 concentration was measured as 82.8 (44.3156.0) ng/mL (Table 1)

Local autocrine plasticity signaling in single dendritic spines by insulin-like growth factors

Patients perception of injectable therapy include perceived difficultly to use and fear of injections

Asia-Pacific is expected to be the fastest growing region in the GLP-1 receptor agonists obesity drugs market during the forecast period due to increasing obesity rates, rising healthcare awareness, and expanding access to advanced diabetes and obesity care Long-acting GLP-1 Receptor Agonists segment dominated the GLP-1 receptor agonists obesity drugs market with a market share of 55.5% in 2024, driven by its superior weight loss efficacy, once-weekly dosing convenience, and broad adoption of drugs such as semaglutide and tirzepatide Report Scope and GLP-1 Receptor Agonists Obesity Drugs Market Segmentation GLP-1 Receptor Agonists Obesity Drugs Market Trends Expansion Beyond Diabetes Through Multi-Indication Approvals A significant and accelerating trend in the global GLP-1 receptor agonists obesity drugs market is the expansion of these therapies beyond type 2 diabetes into broader indications such as chronic obesity, cardiovascular risk reduction, and potentially even conditions such as sleep apnea and nonalcoholic steatohepatitis (NASH)